Activation of oxazaphosphorines by cytochrome P450: Application to gene-directed enzyme prodrug therapy for cancer

Toxicology in Vitro

Volumn 20, Issue 2, 2006, Pages 176-186

  Roy, Partha ^a   Waxman, David J ^b  

^a FOREST RESEARCH INSTITUTE   (United States)

^b Boston University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYPHOSPHAMIDE; 4 HYDROXYTAMOXIFEN; 4 HYROXYIFOSFAMIDE; ADENOVIRUS VECTOR; CYCLOPHOSPHAMIDE; CYTOCHROME P450; DRUG METABOLITE; FLAVOPROTEIN; GANCICLOVIR; IFOSFAMIDE; METHOXYMORPHOLINYL; MORPHOLINE DERIVATIVE; ONCOLYTIC VIRUS; OXAZAPHOSPHORINE DERIVATIVE; PRODRUG; PROPYLTHIOURACIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; RETROVIRUS VECTOR; TAMOXIFEN; THIAMAZOLE; THIOTEPA; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; BREAST CANCER; BYSTANDER EFFECT; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CELL DEATH; CHEMOSENSITIVITY; CLINICAL TRIAL; CYTOTOXICITY; DEFECTIVE VIRUS; DRUG ACTIVATION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG RESISTANCE; DRUG USE; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; GENE THERAPY; HUMAN; IMMUNE RESPONSE; LEUKEMIA; LUNG CANCER; LYMPHOMA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PANCREAS CARCINOMA; SHORT SURVEY; TUMOR CELL; TUMOR CELL DESTRUCTION; URINARY TRACT DISEASE; VIRUS REPLICATION;

ADENOVIRIDAE; RODENTIA;

EID: 30644478786     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2005.06.046     Document Type: Review

References (96)

1. M. Aghi, T.C. Chou, K. Suling, X.O. Breakefield, and E.A. Chiocca Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies Cancer Res. 59 1999 3861 3865
2. M. Aghi, F. Hochberg, and X.O. Breakefield Prodrug activation enzymes in cancer gene therapy J. Gene. Med. 2 2000 148 164
3. L.J. Ayash, J.E. Wright, O. Tretyakov, R. Gonin, A. Elias, C. Wheeler, J.P. Eder, A. Rosowsky, K. Antman, and E.d. Frei Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response J. Clin. Oncol. 10 1992 995 1000
4. J.R. Bischoff, D.H. Kirn, A. Williams, C. Heise, S. Horn, M. Muna, L. Ng, J.A. Nye, A. Sampson-Johannes, A. Fattaey, and F. McCormick An adenovirus mutant that replicates selectively in p53-deficient human tumor cells Science 274 1996 373 376
5. J.L. Borgna, and H. Rochefort Hydroxylated metabolites of tamoxifen are formed in vivo and bound to estrogen receptor in target tissues J. Biol. Chem. 256 1981 859 868
6. K. Borner, J. Kisro, S.K. Bruggemann, W. Hagenah, S.O. Peters, and T. Wagner Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo Drug Metab. Dispos. 28 2000 573 576
7. W. Brade, S. Seeber, and K. Herdrich Comparative activity of ifosfamide and cyclophosphamide Cancer Chemother Pharmacol. 18 1986 S1 S9
8. V.H. Bramwell, H.T. Mouridsen, A. Santoro, G. Blackledge, R. Somers, J. Verwey, P. Dombernowsky, M. Onsrud, D. Thomas, and R. Sylvester Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas Eur. J. Cancer Clin. Oncol. 23 1987 311 321
9. J.P. Braybrooke, A. Slade, G. Deplanque, R. Harrop, S. Madhusudan, M.D. Forster, R. Gibson, A. Makris, D.C. Talbot, J. Steiner, L. White, O. Kan, S. Naylor, M.W. Carroll, S.M. Kingsman, and A.L. Harris Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma Clin. Cancer Res. 11 2005 1512 1520
10. T. Browder, C.E. Butterfield, B.M. Kraling, B. Shi, B. Marshall, M.S. O'Reilly, and J. Folkman Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer Cancer Res. 60 2000 1878 1886
11. S.K. Bruggemann, J. Kisro, and T. Wagner Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide Cancer Res. 57 1997 2676 2680
12. K.D. Bunting, and A.J. Townsend De novo expression of transfected human class 1 aldehyde dehydrogenase (ALDH) causes resistance to oxazaphosphorine anti-cancer alkylating agents in hamster V79 cell lines. Elevated class 1 ALDH activity is closely correlated with reduction in DNA interstrand cross-linking and lethality J. Biol. Chem. 271 1996 11884 11890
13. K.D. Bunting, and A.J. Townsend Protection by transfected rat or human class 3 aldehyde dehydrogenase against the cytotoxic effects of oxazaphosphorine alkylating agents in hamster V79 cell lines. Demonstration of aldophosphamide metabolism by the human cytosolic class 3 isozyme J. Biol. Chem. 271 1996 11891 11896
14. T.K.H. Chang, G.F. Weber, C.L. Crespi, and D.J. Waxman Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes Cancer Res. 53 1993 5629 5637
15. m catalysts of cyclophosphamide and ifosfamide activation Pharmacogenetics 7 1997 211 221
16. M. Chase, R.Y. Chung, and E.A. Chiocca An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy Nature Biotechnol. 16 1998 444 448
17. L. Chen, and D.J. Waxman Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy Cancer Res. 55 1995 581 589
18. G. Chen, and D.J. Waxman Identification of glutathione S-transferase as a determinant of 4-hydroperoxycyclophosphamide resistance in human breast cancer cells Biochem. Pharmacol. 49 1995 1691 1701
19. L. Chen, and D.J. Waxman Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer Curr. Pharm. Des. 8 2002 1405 1416
20. L. Chen, D.J. Waxman, D. Chen, and D.W. Kufe Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene Cancer Res. 56 1996 1331 1340
21. L. Chen, L.J. Yu, and D.J. Waxman Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene Cancer Res. 57 1997 4830 4837
22. Y. Chen, T. DeWeese, J. Dilley, Y. Zhang, Y. Li, N. Ramesh, J. Lee, R. Pennathur-Das, J. Radzyminski, J. Wypych, D. Brignetti, S. Scott, J. Stephens, D.B. Karpf, D.R. Henderson, and D.C. Yu CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity Cancer Res. 61 2001 5453 5460
23. C.S. Chen, J.T. Lin, K.A. Goss, Y.A. He, J.R. Halpert, and D.J. Waxman Activation of the Anticancer Prodrugs Cyclophosphamide and Ifosfamide: Identification of Cytochrome P450 2B Enzymes and Site-Specific Mutants with Improved Enzyme Kinetics Mol. Pharmacol. 65 2004 1278 1285
24. E.A. Chiocca, and D.J. Waxman Cytochrome p450-based gene therapies for cancer Methods Mol. Med. 90 2004 203 222
25. L. Clarke, and D.J. Waxman Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation Cancer Res. 49 1989 2344 2350
26. E.E. Cohen, and C.M. Rudin ONYX-015. Onyx Pharmaceuticals Curr. Opin. Investig. Drugs 2 2001 1770 1775
27. G.U. Dachs, J. Tupper, and G.M. Tozer From bench to bedside for gene-directed enzyme prodrug therapy of cancer Anticancer Drugs 16 2005 349 359
28. S.S. Dehal, and D. Kupfer CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver Cancer Res. 57 1997 3402 3406
29. W.A. Denny Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy) J. Biomed. Biotechnol. 2003 2003 48 70
30. B. Everts, and H.G. van der Poel Replication-selective oncolytic viruses in the treatment of cancer Cancer Gene. Ther. 12 2005 141 161
31. R.A. Fleming An overview of cyclophosphamide and ifosfamide pharmacology Pharmacotherapy 17 1997 146S 154S
32. A. Goldin Ifosphamide in experimental tumor systems Sem. Oncol. 9 1982 14 23
33. M.P. Goren, R.K. Wright, C.B. Pratt, and F.E. Pell Dechloroethylation of ifosfamide and neurotoxicity Lancet 2 1986 1219 1220
34. P.L. Hallenbeck, Y.N. Chang, C. Hay, D. Golightly, D. Stewart, J. Lin, S. Phipps, and Y.L. Chiang A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma Hum. Gene. Ther. 10 1999 1721 1733
35. P.S. Hong, A. Srigritsanapol, and K.K. Chan Pharmacokinetics of 4-hydroxycyclophosphamide and metabolites in the rat Drug Metab. Dispos. 19 1991 1 7
36. Z. Huang, and D.J. Waxman Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitors Cancer Gene. Ther. 8 2001 450 458
37. Z. Huang, P. Roy, and D.J. Waxman Role of human liver microsomal CYP3A4 and CYP2B6 in catalyzing N-dechloroethylation of cyclophosphamide and ifosfamide Biochem. Pharmacol. 59 2000 961 972
38. Z. Huang, M.K. Raychowdhury, and D.J. Waxman Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model Cancer Gene. Ther. 7 2000 1034 1042
39. S. Hunt Technology evaluation: MetXia-P450, Oxford Biomedica Curr. Opin. Mol. Ther. 3 2001 595 598
40. T. Ichikawa, W.P. Petros, S.M. Ludeman, J. Fangmeier, F.H. Hochberg, O.M. Colvin, and E.A. Chiocca Intraneoplastic polymer-based delivery of cyclophosphamide for intratumoral bioconversion by a replicating oncolytic viral vector Cancer Res. 61 2001 864 868
41. Y. Jounaidi Cytochrome P450-based gene therapy for cancer treatment: from concept to the clinic Curr. Drug Metab. 3 2002 609 622
42. Y. Jounaidi, and D.J. Waxman Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy Cancer Res. 61 2001 4437 4444
43. Y. Jounaidi, and D.J. Waxman Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy Cancer Res. 60 2000 3761 3769
44. Y. Jounaidi, and D.J. Waxman Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy Cancer Res. 64 2004 292 303
45. Y. Jounaidi, J.E.D. Hecht, and D.J. Waxman Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy Cancer Res. 58 1998 4391 4401
46. G.P. Kaijser, J.H. Beijnen, E.L. Jeunink, A. Bult, H.J. Keizer, J. de Kraker, and W.J. Underberg Determination of chloroacetaldehyde, a metabolite of oxazaphosphorine cytostatic drugs, in plasma J. Chromatogr. 614 1993 253 259
47. O. Kan, L. Griffiths, D. Baban, S. Iqball, M. Uden, H. Spearman, J. Slingsby, T. Price, M. Esapa, S. Kingsman, A. Kingsman, A. Slade, and S. Naylor Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer Cancer Gene. Ther. 8 2001 473 482
48. O. Kan, S. Kingsman, and S. Naylor Cytochrome P450-based cancer gene therapy: current status Expert Opin. Biol. Ther. 2 2002 857 868
49. A. Kanerva, and A. Hemminki Modified adenoviruses for cancer gene therapy Int. J. Cancer 110 2004 475 480
50. P. Karle, M. Renner, B. Salmons, and W.H. Gunzburg Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide Cancer Gene. Ther. 8 2001 220 230
51. D. Kirn, I. Niculescu-Duvaz, G. Hallden, and C.J. Springer The emerging fields of suicide gene therapy and virotherapy Trends in Molec. Medicine 8 2002
52. E. Lin, and J. Nemunaitis Oncolytic viral therapies Cancer Gene. Ther. 11 2004 643 664
53. M.J. Lind, H.L. Roberts, N. Thatcher, and J.R. Idle The effect of route of administration and fractionation of dose on the metabolism of ifosfamide Cancer Chemother. Pharmacol. 26 1990 105 111
54. M. Lohr, A. Hoffmeyer, J. Kroger, M. Freund, J. Hain, A. Holle, P. Karle, W.T. Knofel, S. Liebe, P. Muller, H. Nizze, M. Renner, R.M. Saller, T. Wagner, K. Hauenstein, W.H. Gunzburg, and B. Salmons Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma Lancet 357 2001 1591 1592
55. M. Lohr, J.C. Kroger, A. Hoffmeyer, M. Freund, J. Hain, A. Holle, W.T. Knofel, S. Liebe, H. Nizze, M. Renner, R. Saller, P. Muller, T. Wagner, K. Hauenstein, B. Salmons, and W.H. Gunzburg Safety, feasibility and clinical benefit of localized chemotherapy using microencapsulated cells for inoperable pancreatic carcinoma in a phase I/II trial Cancer Ther. 1 2003 121 131
56. H. Lu, and D.J. Waxman Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism Mol. Pharmacol. 67 2005 212 219
57. H.O. McCarthy, A. Yakkundi, V. McErlane, C.M. Hughes, G. Keilty, M. Murray, L.H. Patterson, D.G. Hirst, S.R. McKeown, and T. Robson Bioreductive GDEPT using cytochrome P450 3A4 in combination with AQ4N Cancer Gene. Ther. 10 2003 40 48
58. F. McCormick Cancer gene therapy: fringe or cutting edge? Nat. Rev. Cancer 1 2001 130 141
59. F. McCormick Cancer-specific viruses and the development of ONYX-015 Cancer Biol. Ther. 2 2003 S157 S160
60. V. McErlane, A. Yakkundi, H.O. McCarthy, C.M. Hughes, L.H. Patterson, D.G. Hirst, T. Robson, and S.R. McKeown A cytochrome P450 2B6 meditated gene therapy strategy to enhance the effects of radiation or cyclophosphamide when combined with the bioreductive drug AQ4N J. Gene. Med. 2005
61. M.J. Moore Clinical pharmacokinetics of cyclophosphamide Clin. Pharmacokinet. 20 1991 194 208
62. J.S. Moreb, C. Maccow, M. Schweder, and J. Hecomovich Expression of antisense RNA to aldehyde dehydrogenase class-1 sensitizes tumor cells to 4-hydroperoxycyclophosphamide in vitro J. Pharmacol. Exp. Ther. 293 2000 390 396
63. D.A. Muruve The innate immune response to adenovirus vectors Hum. Gene. Ther. 15 2004 1157 1166
64. J. Nemunaitis, C. Cunningham, A. Buchanan, A. Blackburn, G. Edelman, P. Maples, G. Netto, A. Tong, B. Randlev, S. Olson, and D. Kirn Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity Gene. Ther. 8 2001 746 759
65. S.F. Ng, and D.J. Waxman Biotransformation of N,N′,N″- triethylenethiophosphoramide: oxidative desulfuration to yield N,N′,N″-triethylenephosphoramide associated with suicide inactivation of a phenobarbital-inducible hepatic P-450 monooxygenase Cancer Res. 50 1990 464 471
66. T.W. Nicholas, S.B. Read, F.J. Burrows, and C.A. Kruse Suicide gene therapy with Herpes simplex virus thymidine kinase and ganciclovir is enhanced with connexins to improve gap junctions and bystander effects Histol. Histopathol. 18 2003 495 507
67. K. Norpoth Studies on the metabolism of isophosphamide (NSC-109724) in man CTR 60 1976 437 443
68. T.M. Pawlik, H. Nakamura, S.S. Yoon, J.T. Mullen, S. Chandrasekhar, E.A. Chiocca, and K.K. Tanabe Oncolysis of diffuse hepatocellular carcinoma by intravascular administration of a replication-competent, genetically engineered herpesvirus Cancer Res. 60 2000 2790 2795
69. T.M. Pawlik, H. Nakamura, J.T. Mullen, H. Kasuya, S.S. Yoon, S. Chandrasekhar, E.A. Chiocca, and K.K. Tanabe Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene Cancer 95 2002 1171 1181
70. W.P. Peters, M. Ross, J.J. Vredenburgh, B. Meisenberg, L.B. Marks, E. Winer, J. Kurtzberg, R.C. Bast Jr., R. Jones, and E. Shpall High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J. Clin. Oncol. 11 1993 1132 1143
71. G. Quash, G. Fournet, J. Chantepie, J. Gore, C. Ardiet, D. Ardail, Y. Michal, and U. Reichert Novel competitive irreversible inhibitors of aldehyde dehydrogenase (ALDH1): restoration of chemosensitivity of L1210 cells overexpressing ALDH1 and induction of apoptosis in BAF(3) cells overexpressing bcl(2) Biochem. Pharmacol. 64 2002 1279 1292
72. L. Quintieri, A. Rosato, E. Napoli, F. Sola, C. Geroni, M. Floreani, and P. Zanovello In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A Cancer Res. 60 2000 3232 3238
73. M.V. Relling, R. Evans, C. Dass, D.M. Desiderio, and J. Nemec Human cytochrome P450 metabolism of teniposide and etoposide J. Pharmacol. Exp. Ther. 261 1992 491 496
74. S. Ren, J.S. Yang, T.F. Kalhorn, and J.T. Slattery Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes Cancer Res. 57 1997 4229 4235
75. M. Rooseboom, J.N. Commandeur, and N.P. Vermeulen Enzyme-catalyzed activation of anticancer prodrugs Pharmacol. Rev. 56 2004 53 102
76. A.D. Ross, G. Varghese, B. Oporto, F.J. Carmichael, and Y. Israel Effect of propylthiouracil treatment on NADPH-cytochrome P450 reductase levels, oxygen consumption and hydroxyl radical formation in liver microsomes from rats fed ethanol or acetone chronically Biochem. Pharmacol. 49 1995 979 989
77. P. Roy, L.J. Yu, C.L. Crespi, and D.J. Waxman Development of a substrate-activity based approach to identify the major human liver P450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P450 profiles Drug Metab. Dispos. 27 1999 655 666
78. P. Roy, O. Tretyakov, J. Wright, and D.J. Waxman Stereoselective metabolism of ifosfamide by human P450s 3A4 and 2B6. Favorable metabolic properties of R-enantiomer Drug Metab. Dispos. 27 1999 1309 1318
79. K. Saukkonen, and A. Hemminki Tissue-specific promoters for cancer gene therapy Expert Opin. Biol. Ther. 4 2004 683 696
80. P.S. Schwartz, and D.J. Waxman Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells Mol. Pharmacol. 60 2001 1268 1279
81. P.S. Schwartz, C.S. Chen, and D.J. Waxman Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35 Cancer Res. 62 2002 6928 6937
82. P.A. Schwartz, C.S. Chen, and D.J. Waxman Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy Cancer Gene. Therapy 10 2003 571 582
83. R. Skinner, I.M. Sharkey, A.D.J. Pearson, and A.W. Craft Ifosfamide, mesna, and nephrotoxicity in children J. Clin. Oncol. 11 1993 173 190
84. N.E. Sladek Metabolism of oxazaphosphorines Pharmacol. Ther. 37 1988 301 355
85. N.E. Sladek Aldehyde dehydrogenase-mediated cellular relative insensitivity to the oxazaphosphorines Curr. Pharm. Des. 5 1999 607 625
86. T. Thigpen Ifosphamide-induced central nervous system toxicity Gynecol. Oncol. 42 1991 191 192
87. M. Tychopoulos, L. Corcos, P. Genne, P. Beaune, and I. de Waziers A virus-directed enzyme prodrug therapy (VDEPT) strategy for lung cancer using a CYP2B6/NADPH-cytochrome P450 reductase fusion protein Cancer. Gene. Ther. 12 2005 497 508
88. J.M. van Maanen, J. de Vries, D. Pappie, E. van den Akker, V.M. Lafleur, J. Retel, J. van der Greef, and H.M. Pinedo Cytochrome P-450-mediated O-demethylation: a route in the metabolic activation of etoposide (VP-16-213) Cancer Res. 47 1987 4658 4662
89. D. Walker, J.P. Flinois, S.C. Monkman, C. Beloc, A.V. Boddy, S. Cholerton, A.K. Daly, M.J. Lind, A.D.J. Pearson, P.H. Beaune, and J.R. Idle Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide Biochem. Pharmacol. 47 1994 1157 1163
90. D.J. Waxman, and P.S. Schwartz Harnessing apoptosis for improved anti-cancer gene therapy Cancer Res. 63 2003 8563 8572
91. D.J. Waxman, J.J. Morrissey, and G.A. LeBlanc Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase Mol. Pharmacol. 35 1989 519 525
92. D.J. Waxman, L. Chen, J.E.D. Hecht, and Y. Jounaidi Cytochrome P450-based cancer gene therapy: recent advances and future prospects Drug Metab. Rev. 31 1999 503 522
93. G.F. Weber, and D.J. Waxman Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes Biochem. Pharmacol. 45 1993 1685 1694
94. M.X. Wei, T. Tamiya, M. Chase, E.J. Boviatsis, T.K.H. Chang, N.W. Kowall, F.H. Hochberg, D.J. Waxman, X.O. Breakefield, and E.A. Chiocca Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene Hum. Gene. Ther. 5 1994 969 978
95. Y. Yi, S.H. Hahm, and K.H. Lee Retroviral gene therapy: safety issues and possible solutions Curr. Gene. Ther. 5 2005 25 35
96. L.J. Yu, J. Matias, D.A. Scudiero, K.M. Hite, A. Monks, E.A. Sausville, and D.J. Waxman P450 enzyme expression patterns in the NCI human tumor cell line panel Drug Metab. Dispos. 29 2001 304 312